

KFIN/CERT13(3)/SEPT/2025 Date: October 27, 2025

Mr. Ajay Nadkarni

M/s. GlaxoSmithKline Pharmaceuticals Limited

Dr. Annie Besant Road Worli, Mumbai-400025.

Sub: Investor Grievance Certificate for the quarter ended September 30, 2025.

Dear Sir,

With reference to the above, we are pleased to furnish below the status of the Investor complaints under SEBI (Listing Obligations & Disclosure requirements), Regulations, 2015 for the quarter ended September 30, 2025.

Description of Complaint	Opening Balance as on 01.07.2025	Received during the Period 01.07.2025 to 30.09.2025	Attended/Resolved during the Period 01.07.2025 to 30.09.2025	Pending as on 30.09.2025
Non-receipt of Dividend	NIL	NIL	NIL	NIL
Non-receipt of Annual reports	NIL	NIL	NIL	NIL
Non receipt of shares	NIL	NIL	NIL	NIL
SEBI	04	05	06	03
Stock Exchange	NIL	NIL	NIL	NIL
ODR	NIL	01	01	NIL
Total	04	06	07	03

This is for your information and record.

Thanking you,

Yours faithfully

For KFin Technologies Limited

Dnyanesh Gharote

Vice President

KFin Technologies Limited ()

(Formerly known as KFin Technologies Private Limited)

Registered & Corporate Office:

Selenium Building, Tower-B, Plot No- 31 & 32, Financial District, Nanakramguda, Serilingampally, Hyderabad, Rangareddi, Telangana, India, 500032.

CIN: L72400TG2017PLC117649

